Phase 2 open-label study in chronic babesiosis will test a 90-day tafenoquine regimen with a primary patient-reported fatigue endpoint at Day 90 and serial assessments of parasitemia. Up to 100 patients will be enrolled beginning in early November, with follow-up over approximately 12 months and a target of at least 16 participants confirmed positive using the FDA-approved RNA amplification assay used in blood donor screening.
The core move: 60 Degrees Pharmaceuticals is advancing B-FREE, the first interventional trial positioned specifically for chronic babesiosis, repurposing tafenoquine (approved for malaria prophylaxis) under its ARAKODA regimen. The protocol mixes a subjective, functional primary endpoint—the general fatigue subscale of the Multidimensional Fatigue Inventory—with objective virologic assessments, including monthly testing by two CLIA-validated RT-PCR assays and the highly sensitive, non-commercial blood bank RNA assay. Dosing is front-loaded over four days and then weekly through Day 89. The company drove pre-launch engagement by crowdsourcing the study name from patients and directing a modest charitable donation to two Lyme-focused organizations, while operationalizing the study with a CRO and an academic site.
Strategically, this is a high-visibility bet on an underdefined condition. “Chronic babesiosis” is not a uniformly accepted construct in infectious disease practice, and the lack of commercially available, gold-standard diagnostics has constrained prior research. By embedding the blood bank assay as a confirmatory anchor for a subset, the study seeks to quantify how often stringent detection aligns with routine clinical PCRs and whether tafenoquine can clear signal on both fatigue and parasitemia. It is also a repurposing play likely aimed at a 505(b)(2) path, contingent on establishing disease definition, endpoint validity, and benefit-risk in a heterogeneous population. The open-label design lowers execution friction and may accelerate insight generation, but it increases susceptibility to expectation bias on a PRO primary endpoint—an issue regulators and payers will scrutinize.
For sites, the operational footprint is non-trivial despite the weekly dosing cadence. G6PD screening and exclusion are prerequisites, monthly blood sampling is required for six months, and coordination with specialized labs, including access to the non-commercial RNA assay framework, adds logistical complexity. Infectious disease and tick-borne clinics may see strong patient interest given the unmet need, but will need careful triage to align inclusion with the protocol’s functional impairment criteria and confirmatory testing strategy. CROs and central labs will be central to data integrity, particularly around assay concordance, which could influence future diagnostic coverage and availability. For regulators, the study will test whether a hybrid endpoint strategy—fatigue improvement paired with parasite detection and eradication—can form the basis for subsequent randomized development, especially if the sponsor pursues orphan incentives. Vendors with PRO platforms and remote sampling capabilities may find opportunities as the sponsor optimizes burden and retention over a 12-month follow-up.
What to watch next: enrollment velocity and geographic spread as tick seasonality wanes; the proportion of patients with objectively confirmed infection at baseline; concordance between blood bank RNA detection and commercial PCRs; the durability of fatigue improvements beyond Day 90; and signal on parasite eradication in those with confirmed infection. Any safety or tolerability flags, particularly those requiring additional monitoring infrastructure, could alter site readiness and design choices for a pivotal program. The pivotal question is whether this open-label signal can crystallize a definable patient population, reproducible diagnostics, and a regulator-acceptable endpoint hierarchy. Absent that, a randomized, controlled study with an objective primary outcome will be unavoidable—and the sponsor’s ability to standardize diagnostics may determine whether that trial is even feasible.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
